Evidence map›Paper›PMID 40997098›Full record

ArticlePLoS computational biology2025

A comparative computational analysis of IFN-alpha pharmacokinetics and its induced cellular response in mice and humans.

Priyata Kalra, Bastian Kister, Rebekka Fendt, Mario Köster, Julia Pulverer, Sven Sahle, Lars Kuepfer, Ursula Kummer

Abstract readComparative Study
In one paragraph

Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Priyata KalraDepartment of Modelling of Biological Processes, COS/BioQuant, Heidelberg University, Heidelberg, Germany.
Bastian KisterDepartment of Modelling of Biological Processes, COS/BioQuant, Heidelberg University, Heidelberg, Germany.
Rebekka FendtDepartment of Modelling of Biological Processes, COS/BioQuant, Heidelberg University, Heidelberg, Germany.
Mario KösterModel System for Infection and Immunity, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Julia PulvererModel System for Infection and Immunity, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Sven SahleDepartment of Modelling of Biological Processes, COS/BioQuant, Heidelberg University, Heidelberg, Germany.
Lars KuepferInstitute for Systems Medicine with Focus on Organ Interaction, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0002-8741-7786
Ursula KummerDepartment of Modelling of Biological Processes, COS/BioQuant, Heidelberg University, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug effects are difficult to investigate in detail in vivo. However, a mechanistic understanding of drug action is clearly beneficial for both pharmaceutical development as well as for optimization of treatment designs. We here established a quantitative systems pharmacology (QSP) mouse model which simultaneously describes whole-body pharmacokinetics of murine IFN-α as well as the cellular pharmacodynamic effect through the antiviral response biomarker Mx2. To this end, a dynamic model of intracellular IFN-α signalling in the JAK/STAT pathway was combined with a whole-body physiologically-based pharmacokinetic model of IFN-α in mice. The pharmacodynamic behaviour of the resulting mouse IFN-α QSP model was first compared to a cellular model of the JAK/STAT pathway to compare in vitro and in vivo drug effects and to identify functional differences. It was found that the in vitro drug effect in the cellular model overestimates the in vivo response in mice at least by a factor of two which is partly due to the missing drug clearance in vitro. Also, the drug responses in the in vitro model were time delayed. Interspecies analyses in murine and a previously published human QSP model of IFN-α next show a similar dynamic behavior. However, our models demonstrate eight to 16-fold stronger response levels in mice than in humans due to more efficient interferon binding. Our analysis supports a mechanistic analysis of both upstream pharmacokinetic as well as downstream pharmacodynamic drug effects through the combination of physiological knowledge and quantitative computational models. The study hence shows potential applications for QSP modelling in terms of study planning, for example by choosing physiologically relevant in vitro concentrations. Also, the QSP model allows inter-species comparisons of the effect strength in specific functional readouts, which in humans are otherwise not possible due to the limited sampling possibilities. We expect QSP modelling to play an increasingly important role in drug development and research in the future.

Indexed as

Interferon-alphaModels, BiologicalAnimalsComputational BiologyComputer SimulationHumansMiceSignal TransductionInterferon-alpha

Identifiers

PMID40997098
PMCPMC12500084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.